Clinical trials: Minimal Residual Disease
Acute Myeloid Leukemia
Pilot Evaluation of a Microfluidic Assay to Detect Minimal Residual Disease and Predict Relapse in AML Patients
Purpose: The purpose of this trial is to investigate whether a microfluidics assay can detect trace amounts of residual leukemia and predict relapse in acute myeloid leukemia (AML) patients in remission who have undergone…
- Trial name
- NCT03488862
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Cervical Cancer
Optimization of Postoperative Adjuvant Therapy for Cervical Cancer Based on MRD(Minimal Residual Disease)
This study is a prospective cohort clinical trial that aims to investigate the safety and efficacy of a combined chemoradiotherapy and immunotherapy treatment for early postoperative cervical cancer.
- Trial name
- NCT05872724
- Testing
- Chemoradiotherapy + Adjuvant chemotherapy and Zimberelimab, Chemoradiotherapy (small pelvic) + Zimberelimab
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Suzhou Municipal Hospital
Non-Small Cell Lung Cancer
A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC)
In this study, the researchers will look at whether having participants switch from durvalumab to sotorasib when they have detectable minimal residual disease (MRD) is an effective treatment approach for locally advanced…
- Trial name
- NCT06333678
- Testing
- Durvalumab, Sotorasib
- Where
- 10 sites in United States
- Volunteers
- 10 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Stem Cell Transplant Complications, Leukemia, Myeloid, Acute
Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT
Allogeneic haematopoietic stem cell transplantation (allo-HSCT) remains one of the currently available curative therapies for acute leukemia (AL). Leukemia relapse is one of the mainly causes of transplant failure.
- Conditions
- Stem Cell Transplant Complications, Leukemia, Myeloid, Acute, Leukemia Relapse
- Trial name
- NCT03793517
- Testing
- Decitabine, mBU/CY and ATG, mBU/CY
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Peking University People's Hospital
Acute Lymphoid Leukemia, Minimal Residual Disease
Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil
In this project, the investigators intend to start a prospective registry for patients with newly diagnosed Philadelphia-negative ALL from 16 years old and above in participating centers, provided that all patients will be…
- Conditions
- Acute Lymphoid Leukemia, Minimal Residual Disease, Gene Abnormality, Chemotherapeutic Toxicity
- Trial name
- BRALLA (NCT05959720)
- Testing
- Prednisone, Vincristin, Daunorubicin
- Where
- Brazil
- Volunteers
- 180 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Relapsed/Refractory Large B-cell Lymphoma
MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma
This is a Phase II open-label, two-arm randomised non-comparative, multi-centre study to evaluate the efficacy of Epcor-only (Epcoritamab alone) or Epcor-R2 (Epcoritamab, lenalidomide and rituximab) as consolidation post…
- Trial name
- EpLCART (NCT06414148)
- Testing
- Epcoritamab, Epcoritamab, lenalidomide and rituximab
- Where
- 6 sites in Australia
- Volunteers
- 40 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Carcinoma, Non-Small-Cell Lung, Next-Generation Sequencing
Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLC
This clinical trial aims to explore the minimal residual disease (MRD) status of early NSCLC after curative surgery and the clinical outcomes of adjuvant chemotherapy.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Next-Generation Sequencing, Chemotherapy, Adjuvant, Neoplasm, Residual
- Trial name
- NCT05167604
- Testing
- Adjuvants, Pharmaceutic
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Tang-Du Hospital
IgG4-Related Diseases
A Study on the Effect of MRD Detected by FAPI PET / CT on the Recurrence of IgG4-RD
This study intends to use the new technology of fibroblast activation protein PET / CT to study whether the tiny residual lesions detected by 68Ga-FAPI PET / CT are related to the recurrence of IgG4-RD in patients with IgG4-RD…
- Trial name
- NCT07104058
- Testing
- 68Ga-FAPI PET / CT
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Luo Yaping
Non-Small Cell Lung Cancer
Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC
This investigator-initiated study aims to evaluate the effectiveness of minimal residual disease (MRD) as a biomarker for guiding adjuvant therapy decisions in patients with Stage I non-small-cell lung cancer (NSCLC).
- Trial name
- MOTION-NSCLC (NCT06709274)
- Testing
- Osimertinib, Alectinib, TORIPALIMAB INJECTION (JS001 ) combine with chemotherapy
- Where
- 15 sites in China
- Volunteers
- 342 people
- Sponsor
- Guangdong Association of Clinical Trials
Diffuse Large B-Cell Lymphoma
MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma
This prospective feasibility study evaluates a minimal residual disease (MRD)-adapted treatment strategy in patients with diffuse large B-cell lymphoma (DLBCL) receiving frontline chemoimmunotherapy.
- Trial name
- NCT07517705
- Testing
- Low-Dose Radiation Therapy (LDRT), Standard Frontline Chemoimmunotherapy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Nebraska
Myeloma
Place of the Hevylite Test in the Evaluation of MRD in Myeloma
Study aiming at testing the positive predictive value of the Hevylite blood test in detecting minimal residual disease in myeloma compared to an invasive method requiring bone marrow sample by multi-parametric flow cytometry
- Trial name
- NCT03702088
- Where
- France
- Volunteers
- 124 people
- Sponsor
- University Hospital, Montpellier
HCC, Minimal Residual Disease
Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC
Hepatocellular carcinoma (HCC) is a leading global cause of cancer-related mortality. While curative resection is pivotal, high postoperative recurrence rates remain a major challenge.
- Conditions
- HCC, Minimal Residual Disease, Recurrence
- Trial name
- NCT07350824
- Testing
- Adjuvant PD-1 inhibitors, Active monitoring
- Where
- China
- Volunteers
- 276 people
- Sponsor
- Tongji Hospital
Acute Myeloid Leukemia, Acute Lymphoblastic T-cell Leukemia
Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell Transplantation
This pilot clinical trial aims to evaluate the feasibility, adverse reactions and maximum tolerated dose of mbIL21 ex vivo-expanded donor-derived NK-cell infusions before and after haploidentical or matched-related hematopoietic…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic T-cell Leukemia, Mixed Phenotype Acute Leukemia
- Trial name
- NCT07256210
- Testing
- Donor-derived Natural Killer Cell
- Where
- Russia
- Volunteers
- 15 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Myeloma
Non-invasive MRD Assessment in Multiple Myeloma
The purpose of this study is to investigate the sensitivity and accuracy of non-invasive MRD assessment using liquid biopsy (blood draw) and functional imaging (whole body MRI) in participants with new diagnosed and previously…
- Trial name
- NIRVANA (NCT05625971)
- Testing
- MRD Assessment
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Rajshekhar Chakraborty, MD
Minimal Residual Disease
Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease
This is an open-label, Phase I study of QN-030a (allogeneic NK cell therapy) in Acute Myeloid Leukemia Minimal Residual Disease(AML MRD).
- Trial name
- NCT05601830
- Testing
- QN-030a, Cyclophosphamid, Fludarabine
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Leukemia
Collection of Blood and Bone Marrow Samples From Select Patients With CML to Measure Minimal Residual Disease
Although allogeneic stem cell transplantation is curative in CML, evidence of the BCR-ABL oncogene at low levels is still found in long-term follow-up of survivors.
- Trial name
- NCT00819143
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
B-cell Non-Hodgkin Lymphoma, Aggressive
DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas
The purpose of this study is to determine whether a blood test can accurately detect whether if the participant's lymphoma has come back after completion of initial chemotherapy treatment for their aggressive B-cell Non-Hodgkin…
- Trial name
- NCT02633111
- Testing
- collected at pre-treatment tumor biopsy, Peripheral blood tests, PET/CT
- Where
- 12 sites in United States
- Volunteers
- 501 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Leukemia, Leukemia, Myeloid
Natural Killer Cell (CYNK-001) Infusions in Adults with AML
This study will find the maximum tolerated dose or the maximum planned dose of CYNK-001 which contains natural killer (NK) cells derived from human placental CD34+ cells and culture-expanded.
- Conditions
- Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Neoplasms by Histologic Type
- Trial name
- CYNK001AML01 (NCT04310592)
- Testing
- CYNK-001
- Where
- 10 sites in United States
- Volunteers
- 27 people
- Sponsor
- Celularity Incorporated
Metastatic Bone Sarcoma, Metastatic Malignant Neoplasm in the Lung
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
This phase I/II trial studies the side effects of pulmonary suffusion in controlling minimal residual disease in patients with sarcoma or colorectal carcinoma that has spread to the lungs.
- Conditions
- Metastatic Bone Sarcoma, Metastatic Malignant Neoplasm in the Lung, Metastatic Soft Tissue Sarcoma, Metastatic Unresectable Sarcoma
- Trial name
- NCT03965234
- Testing
- Cisplatin, Isolated Chemotherapeutic Lung Perfusion, Metastasectomy
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- Roswell Park Cancer Institute
Breast Neoplasms
Sweden Cancerome Analysis Network - Breast : Genomic Profiling of Breast Cancer
This study evaluates the genomic profiles of breast cancer in a prospective and population-based manner. In the first phase, breast tumors are analyzed by whole transcriptome RNA-sequencing.
- Trial name
- SCAN-B (NCT02306096)
- Where
- 10 sites in Sweden
- Volunteers
- 20,000 people
- Sponsor
- Lund University